Can theranostics be the key to completely curing colorectal cancer?

November 7, 2017

Historically, radioimmunotherapy has been an imperfect fit for treating solid tumors, but a new study published in The Journal of Nuclear Medicine suggests that may be changing.

In a preclinical experiment, a new theranostic approach for treating colorectal cancer achieved a 100 percent cure rate with no toxic side effects.

A research team from Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology tested the three-step approach on a mouse model. They focused on an antigen present in over 95 percent of primary and metastatic colorectal cancers in humans called glycoprotein A33.